# Piriformis Syndrome Market

> Piriformis Syndrome Market Research Report Information By Cause (Trauma, Spasms, Others), Diagnostic Test (MRI, Others), Treatment (Medication, Physical Therapy, Others), Distribution Channel (Retail Pharmacies, Others), End-User – Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.59%
- **2024:** $ 0.27 Million
- **2025:** $ 0.29 Million
- **2035:** $ 0.54 Million
- **Key Players:** Medtronic (US), Johnson & Johnson (US), Stryker (US), Boston Scientific (US), Abbott Laboratories (US), Smith & Nephew (GB), Zimmer Biomet (US), DePuy Synthes (US)

**Report ID:** MRFR/Pharma/4788-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/piriformis-syndrome-market-6249

---

## Market Summary

## **Piriformis Syndrome Market Overview**

The Piriformis Syndrome Market is expected to reach USD 245.44 Million by 2030 at 6.10% CAGR during the forecast period 2022-2030.

Piriformis syndrome is a rare neuromuscular condition that is caused when the piriformis muscle compresses the sciatic nerve. The piriformis muscle is a flat, band-like muscle located in the buttock near the upper region of the hip joint. Piriformis syndrome mostly occurs in adults and can affect individuals from any field and activity levels. The common causes of piriformis syndrome are considered to be trauma, spasms, and overuse injury. Additionally, according to the National Center for Biotechnology Information (NCBI), the piriformis syndrome is more prevalent in patients with pain in the lower back.

The piriformis syndrome market is majorly driven by the increase in the occurrences of piriformis syndrome, increasing screening, rising safety and success of drug treatments, and the growing geriatric population. The market restraints include the complications of surgeries, lack of awareness about the syndrome, and others. Furthermore, challenges in the diagnosis of the syndrome among the patient pool may hamper the growth of the market.

**Research Methodology**

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the piriformis syndrome market. It was also used to obtain key information about major players, [market classification](../../../reports/data-classification-market-7378) and segmentation according to the industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.

## **Key Players in the Piriformis Syndrome Market**

## **Piriformis Syndrome Market Segmentation**

The piriformis syndrome market is segmented on the basis of cause, diagnostic test, treatment, distribution channel, and end-user.

On the basis of cause, the market is classified as trauma, spasms, overuse injury, and others.

The piriformis syndrome market on the basis of diagnostic tests is segmented as Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), neurophysiologic testing, Electromyography (EMG), Beatty Test, FAIR (Flexion, adduction, and Internal Rotation) test, and others.

On the basis of treatment, the market is segmented into medication, physical therapy, acupuncture, prolotherapy, Osteopathic Manipulative Treatment (OMT), surgery, and others. The medication is further segmented into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), piriformis muscle injection, and others. NSAIDs are further segmented into naproxen, ibuprofen, and others. Further, the piriformis muscle injection is segmented into Botox injection, steroid injections, and others.

The piriformis syndrome market, by distribution channel, is segmented into E-commerce, retail pharmacies, and others.

On the basis of end-user, the market is segmented as hospitals and clinics, diagnostic centers, and others.

Geographically, the piriformis syndrome market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American market is further segmented into North America and South America. North America is further classified as the US and Canada.

The European piriformis syndrome market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The piriformis syndrome market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.

The Middle Eastern and African market is segmented into the Middle East and Africa.

## **Piriformis Syndrome Market Regional Analysis**

The piriformis syndrome market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the market due to the existing well-established healthcare system, increasing healthcare expenditure, growing awareness about the syndrome, and rising geriatric population. 

For instance, according to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the US was reported to be 3.2 USD trillion. Additionally, the high concentration of major hospitals in developed countries of this region coupled with good reimbursement rates is fueling the growth of the market. Moreover, a large number of prominent companies in the US is likely to contribute to the faster development of the piriformis syndrome market in this region.

Europe is expected to hold the second largest market share in the market. It is expected that the government support towards research and development expenditure and increasing secondary lifestyle are likely to drive the market.  Moreover, the market growth in Europe is led by countries such as Germany and France.

The piriformis syndrome market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The market growth in this region is driven by the rising healthcare expenditure and growing penetration of the healthcare industry in this region.

The Middle East & Africa holds the lowest share of the piriformis syndrome market. The African region is anticipated to witness a poor market growth owing to poor economic and political conditions and poor healthcare infrastructure.

**The Market of Piriformis syndrome, by Cause**

**The Market of Piriformis syndrome, by Diagnostic Test**

**The Market of Piriformis syndrome, by Treatment**

**The Market of Piriformis syndrome, by Distribution Channel**

**The Market of Piriformis syndrome, by End-User**

**The Market of Piriformis syndrome, by Region**

**Intended Audience**

## Market Drivers

### Market Growth Projections

The Global Piriformis Syndrome Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 171.9 USD Million in 2024, the industry is expected to reach 330.0 USD Million by 2035. This growth trajectory suggests a compound annual growth rate of 6.11% from 2025 to 2035. Such projections indicate a robust demand for effective treatment options and highlight the increasing recognition of Piriformis Syndrome Market as a significant health concern. The market's expansion reflects the ongoing efforts to improve patient care and enhance treatment modalities.

### Increased Awareness and Diagnosis

The growing awareness of Piriformis Syndrome Market among healthcare professionals and the general public is a significant driver for the Global Piriformis Syndrome Market Industry. Enhanced education and training for clinicians lead to more accurate diagnoses, which in turn encourages patients to seek treatment. Public health campaigns and resources available online contribute to this awareness, helping individuals recognize symptoms earlier. As a result, the market is likely to see an increase in demand for diagnostic tools and therapeutic interventions. This heightened awareness is expected to support the market's growth trajectory, with projections indicating a rise to 330.0 USD Million by 2035.

### Integration of Telehealth Services

The integration of telehealth services into the management of Piriformis Syndrome Market is transforming the Global Piriformis Syndrome Market Industry. Telehealth offers patients convenient access to healthcare professionals, particularly for those in remote areas or with mobility challenges. This shift not only enhances patient engagement but also facilitates timely diagnosis and treatment. As telehealth continues to gain traction, it is likely to expand the reach of healthcare providers and improve patient outcomes. The ongoing evolution of telehealth services may further stimulate market growth, as more patients utilize these platforms for managing their conditions.

### Advancements in Treatment Modalities

Innovations in treatment options for Piriformis Syndrome Market are propelling the Global Piriformis Syndrome Market Industry forward. Recent advancements include minimally invasive surgical techniques, physical therapy, and the use of targeted injections. These developments enhance patient outcomes and reduce recovery times, making treatment more appealing. Furthermore, the introduction of new therapeutic devices and medications is likely to improve the management of this condition. As the market evolves, it is anticipated that the Global Piriformis Syndrome Market will experience a compound annual growth rate of 6.11% from 2025 to 2035, driven by these advancements.

### Rising Prevalence of Piriformis Syndrome

The increasing incidence of Piriformis Syndrome Market is a notable driver for the Global Piriformis Syndrome Market Industry. Factors such as sedentary lifestyles and the growing aging population contribute to this trend. Reports indicate that the prevalence of this condition is rising, particularly among individuals engaged in repetitive activities or prolonged sitting. As awareness of this syndrome grows, more patients seek medical intervention, thereby expanding the market. The Global Piriformis Syndrome Market is projected to reach 171.9 USD Million by 2024, reflecting the urgent need for effective treatment options and management strategies.

### Growing Demand for Rehabilitation Services

The increasing demand for rehabilitation services for individuals suffering from Piriformis Syndrome Market is a crucial driver for the Global Piriformis Syndrome Market Industry. Rehabilitation programs focusing on physical therapy, exercise regimens, and [pain management](https://www.marketresearchfuture.com/reports/pain-management-market-5975) are becoming more prevalent. This trend is largely influenced by the rising number of patients seeking non-invasive treatment options. As healthcare systems prioritize rehabilitation to improve quality of life, the market is expected to expand significantly. The emphasis on holistic approaches to treatment aligns with the growing preference for personalized care, further supporting the market's development.

## Future Outlook

The Piriformis Syndrome Market is projected to grow at a 6.59% CAGR from 2025 to 2035, driven by increasing awareness, innovative treatment options, and rising healthcare expenditures.

**New opportunities:**

- Development of telehealth platforms for remote consultations and treatment plans.
- Investment in targeted physical therapy programs tailored for Piriformis Syndrome patients.
- Creation of specialized ergonomic products to alleviate symptoms in workplaces.

By 2035, the Piriformis Syndrome Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Treatment Type: Physical Therapy (Largest) vs. Medication (Fastest-Growing)

In the Piriformis Syndrome Market, the treatment type segment showcases a diverse array of options, with Physical Therapy holding the largest market share. This is primarily due to the rising acceptance of non-invasive treatment methods, which emphasize rehabilitation and recovery through carefully structured exercises. Medication, on the other hand, has shown significant growth potential as more patients seek immediate relief from pain through pharmaceuticals, particularly anti-inflammatory drugs and muscle relaxants.

Growth trends in this market segment are being driven by increased awareness of Piriformis Syndrome and its effects on quality of life. As research continues to validate the efficacy of conservative treatments, Physical Therapy remains the stronghold while Medication is rapidly gaining ground. The emergence of novel drugs and the integration of telehealth for personalized [medication management](https://www.marketresearchfuture.com/reports/medication-management-market-7187) further fuel the expansion of this segment.

Physical Therapy (Dominant) vs. Medication (Emerging)

Physical Therapy is the dominant treatment for Piriformis Syndrome due to its foundational approach of addressing the root causes of pain through physical rehabilitation. It is often tailored to individual patient needs, focusing on exercises that enhance strength, flexibility, and overall function, which can lead to long-term relief. On the other hand, Medication presents an emerging option that complements physical treatment, providing patients with necessary pain relief and inflammation reduction. With advancements in pharmacological treatments and a shift towards more holistic management of pain, this segment is witnessing rapid innovation. These two modalities signify a comprehensive approach to managing Piriformis Syndrome, balancing immediate relief with long-term recovery strategies.

### By Diagnosis Method: Physical Examination (Largest) vs. MRI Scan (Fastest-Growing)

In the Piriformis Syndrome Market, diagnosis methods such as Physical Examination have established a substantial presence, representing the largest share within this segment. While Physical Examination remains a critical component in assessing the condition's severity, MRI Scans are emerging as the method with the fastest growth rate. Their ability to provide detailed imaging of soft tissues has increased their utilization among healthcare professionals, leading to a notable shift toward advanced diagnostic techniques.

The growth trends for diagnosis methods in the Piriformis Syndrome Market are driven by advances in imaging technology and the need for accurate diagnoses. MRI Scans, in particular, are benefiting from technological enhancements, enabling clearer and more precise visualizations. Simultaneously, awareness about the syndrome among practitioners and patients is boosting the adoption of various diagnostic methods, enhancing overall market dynamics and providing diverse options for clinical assessments.

Physical Examination (Dominant) vs. Nerve Conduction Study (Emerging)

The Physical Examination remains the dominant diagnosis method in the Piriformis Syndrome Market due to its accessibility, effectiveness, and cost-efficiency. This traditional method allows healthcare providers to assess the patient's physical condition and identify piriformis syndrome symptoms through basic tests and evaluations. On the other hand, the Nerve Conduction Study is an emerging technique gaining traction in diagnosing nerve-related issues associated with the syndrome. It involves testing the electrical conduction of nerves, helping in identifying nerve entrapment and related conditions. The growing emphasis on comprehensive diagnostic approaches is likely to position the Nerve Conduction Study as a valuable tool in the assessment arsenal for Piriformis Syndrome.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Piriformis Syndrome Market, the distribution of patient demographics reveals that age group holds the largest share of patients suffering from this condition, primarily affecting individuals aged between 30-50 years. This demographic represents a significant portion of the total market due to their active lifestyles, which can contribute to the onset of piriformis syndrome. Gender also plays a crucial role, with a growing number of women being diagnosed, indicating an increasing recognition of the syndrome's prevalence among female patients.

Age Group (Dominant) vs. Gender (Emerging)

The age group segment, particularly individuals aged 30-50 years, proves to be the dominant force in the Piriformis Syndrome Market due to their higher likelihood of engaging in activities that can lead to irritation of the sciatic nerve. This age bracket is often characterized by physical jobs or hobbies that exacerbate the condition. Meanwhile, the gender segment is emerging, reflecting a noteworthy trend where women, historically underrepresented, are increasingly diagnosed with piriformis syndrome. Awareness and outreach programs are pivotal in identifying and treating this condition in women, leading to expected growth in female patient numbers in the near future.

### By Severity Level: Mild (Largest) vs. Severe (Fastest-Growing)

The Piriformis Syndrome market is characterized by varying severity levels, with 'Mild' symptoms commanding the largest market share. This segment appeals to a broad demographic, as individuals often seek early intervention for manageable pain. The distribution among 'Moderate', 'Severe', 'Chronic', and 'Acute' levels reflects the nuanced understanding of patient needs, with 'Moderate' and 'Severe' also capturing significant attention due to their relative prevalence among affected individuals. 'Chronic' and 'Acute' categories, while vital, contribute to a smaller fraction of the market, indicating varied treatment complexities.

Growth trends highlight an increasing focus on acute and severe Piriformis Syndrome cases, driven by heightened awareness and advancements in therapeutic options. Factors such as innovative treatment modalities, the rise of specialty clinics, and increased patient education have contributed to the swift growth of the severe category. Furthermore, the chronic nature of some cases continues to necessitate improvements in management strategies, promoting ongoing research and development in targeted therapies.

Mild (Dominant) vs. Severe (Emerging)

The 'Mild' severity level represents a dominant segment in the Piriformis Syndrome market, characterized by lower intensity symptoms that often lead patients to pursue conservative treatment options. Individuals in this category tend to experience occasional discomfort, resulting in a proactive approach to management through physiotherapy and lifestyle adjustments. In contrast, the 'Severe' segment is emerging as a critical focus for healthcare providers, driven by increasing awareness and more comprehensive treatment protocols. Patients experiencing severe symptoms often require more aggressive intervention, potentially including surgical options. This differentiation in severity shapes treatment pathways and patient engagement, influencing the overall market dynamics as stakeholders adapt to the evolving landscape.

### By Healthcare Setting: Outpatient Clinic (Largest) vs. Hospital (Fastest-Growing)

The healthcare setting for the Piriformis Syndrome market is diverse, with outpatient clinics holding the largest share of the market. These clinics are pivotal in providing accessible treatments and quick interventions for patients suffering from piriformis syndrome. Hospitals also occupy a significant place in this landscape, but their market share is growing rapidly due to increasing recognition of more complex cases that require comprehensive care and advanced treatment options.

Outpatient Clinic (Dominant) vs. Hospital (Emerging)

Outpatient clinics serve as the dominant setting in the Piriformis Syndrome market, offering targeted interventions and a convenient environment for patients. Their personalized approach and emphasis on non-invasive treatments appeal to many individuals seeking relief. In contrast, hospitals, labeled as an emerging setting, are stepping up their game to cater to the more complex cases of piriformis syndrome. The increase in surgical interventions and integrated care protocols in hospitals is aimed at accommodating patients with multifaceted issues, driving their growth in this market.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Piriformis Syndrome market, holding a significant market share of 13.4% in 2024. The region's growth is driven by increasing awareness of the condition, advancements in medical technology, and a robust healthcare infrastructure. Regulatory support for innovative treatments and therapies further fuels demand, making it a key player in the global market.

The United States stands out as the leading country, with major players like Medtronic, Johnson & Johnson, and Stryker driving competition. The presence of advanced healthcare facilities and a high prevalence of musculoskeletal disorders contribute to the market's expansion. As the region continues to innovate, it attracts investments aimed at enhancing treatment options for Piriformis Syndrome.

### Europe : Emerging Market with Growth Potential

Europe is witnessing a growing interest in the Piriformis Syndrome market, with a market share of 8.6% in 2024. Factors such as an aging population, increased healthcare spending, and a focus on pain management are driving demand. Regulatory frameworks in countries like Germany and France are evolving to support innovative treatment options, enhancing market growth prospects across the region.

Leading countries include Germany, France, and the UK, where key players like Smith & Nephew and Zimmer Biomet are actively involved. The competitive landscape is characterized by collaborations and partnerships aimed at developing advanced therapeutic solutions. As healthcare systems adapt to meet patient needs, the market is expected to expand significantly in the coming years.

### Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is emerging as a significant player in the Piriformis Syndrome market, with a market share of 3.8% in 2024. The growth is driven by rising healthcare expenditures, increasing awareness of musculoskeletal disorders, and a growing population. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to boost demand for effective treatment options in the coming years.

China and Japan are leading the market, with a competitive landscape featuring both local and international players. Companies are focusing on expanding their product offerings and enhancing distribution channels to capture a larger market share. As the region continues to develop, it presents lucrative opportunities for growth in the Piriformis Syndrome market.

### Middle East and Africa : Resource-Rich Frontier for Healthcare

The Middle East and Africa region is gradually emerging in the Piriformis Syndrome market, holding a market share of 1.0% in 2024. The growth is primarily driven by increasing healthcare investments, a rising prevalence of lifestyle-related disorders, and a focus on improving healthcare access. Governments are implementing policies to enhance healthcare infrastructure, which is expected to support market growth in the coming years.

Leading countries in this region include South Africa and the UAE, where healthcare systems are evolving to meet patient needs. The competitive landscape is characterized by a mix of local and international players, with companies focusing on establishing a presence in the region. As healthcare continues to improve, the market for Piriformis Syndrome treatments is anticipated to grow steadily.

## Competitive Benchmarking

The Piriformis Syndrome Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Medtronic (US), Johnson & Johnson (US), and Stryker (US) are actively engaged in enhancing their product offerings and expanding their market presence. Medtronic (US) has positioned itself as a leader in neuromodulation therapies, which are crucial for managing pain associated with Piriformis Syndrome. Meanwhile, Johnson & Johnson (US) emphasizes a diversified portfolio that includes surgical instruments and advanced imaging technologies, aiming to streamline treatment processes. Stryker (US) focuses on integrating digital health solutions into its surgical products, thereby enhancing operational efficiency and patient outcomes. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and operational excellence are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain resilience. This approach is particularly relevant in the context of the Piriformis Syndrome Market, which is moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they not only drive technological advancements but also set industry standards that smaller companies must adhere to.

In November  Medtronic (US) announced the launch of a new neuromodulation device specifically designed for chronic pain management, including Piriformis Syndrome. This strategic move is expected to enhance Medtronic's market share by addressing unmet needs in pain management, thereby reinforcing its leadership position. The introduction of this device aligns with the growing trend towards personalized medicine, which is becoming increasingly important in the treatment of musculoskeletal disorders.

In October  Johnson & Johnson (US) entered into a partnership with a leading telehealth provider to enhance [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) capabilities for individuals suffering from Piriformis Syndrome. This collaboration is strategically significant as it not only expands Johnson & Johnson's digital health footprint but also facilitates better patient engagement and adherence to treatment protocols. The integration of telehealth solutions is likely to improve patient outcomes and streamline care delivery.

In September  Stryker (US) acquired a small but innovative company specializing in AI-driven surgical planning tools. This acquisition is indicative of Stryker's commitment to integrating advanced technologies into its product offerings, which could potentially revolutionize surgical approaches for Piriformis Syndrome. By leveraging AI, Stryker aims to enhance precision in surgical procedures, thereby improving recovery times and overall patient satisfaction.

As of December  the Piriformis Syndrome Market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise to drive innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and deliver superior patient outcomes, as companies navigate an evolving market landscape.

## Report Scope

| MARKET SIZE 2024 | 0.268(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 0.289(USD Million) |
| MARKET SIZE 2035 | 0.544(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.59% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Johnson & Johnson (US), Stryker (US), Boston Scientific (US), Abbott Laboratories (US), Smith & Nephew (GB), Zimmer Biomet (US), DePuy Synthes (US) |
| Segments Covered | Treatment Type, Patient Demographics, Symptom Severity, Diagnosis Method |
| Key Market Opportunities | Advancements in non-invasive treatment options for Piriformis Syndrome enhance patient outcomes and market potential. |
| Key Market Dynamics | Rising demand for non-invasive treatment options drives innovation in the Piriformis Syndrome market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Piriformis Syndrome Market in 2035?**
A: The projected market valuation for the Piriformis Syndrome Market in 2035 is expected to reach 0.544 USD Million.

**Q: What was the overall market valuation for the Piriformis Syndrome Market in 2024?**
A: The overall market valuation for the Piriformis Syndrome Market in 2024 was 0.268 USD Million.

**Q: What is the expected CAGR for the Piriformis Syndrome Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Piriformis Syndrome Market during the forecast period 2025 - 2035 is 6.59%.

**Q: Which companies are considered key players in the Piriformis Syndrome Market?**
A: Key players in the Piriformis Syndrome Market include Medtronic, Johnson & Johnson, Stryker, and Boston Scientific.

**Q: What treatment type segment had the highest valuation in 2024?**
A: In 2024, the Physical Therapy segment had the highest valuation at 0.1648 USD Million.

**Q: How does the market perform in terms of diagnosis methods for Piriformis Syndrome?**
A: The MRI Scan segment shows a valuation of 0.174 USD Million, indicating strong performance in diagnosis methods.

**Q: What demographic factors are influencing the Piriformis Syndrome Market?**
A: Factors such as Age Group and Gender are influencing the market, with valuations of 0.1 USD Million and 0.12 USD Million, respectively.

**Q: What is the market outlook for outpatient clinics in the Piriformis Syndrome Market?**
A: The outpatient clinic segment is projected to maintain a valuation of 0.136 USD Million, reflecting its importance in healthcare settings.

**Q: Which severity level segment is expected to show growth in the coming years?**
A: The Moderate severity level segment, valued at 0.162 USD Million, is expected to show growth in the coming years.

**Q: How does the Piriformis Syndrome Market compare across different healthcare settings?**
A: In 2024, the Hospital segment led with a valuation of 0.164 USD Million, suggesting a preference for treatment in hospital settings.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/piriformis-syndrome-market-6249*